Form 4: BioCardia SVP Gillis Receives Equity Compensation

BioCardia's Senior Vice President, Edward M. Gillis, received significant equity compensation through RSU vesting and new stock option grants.

Summary

• Edward M. Gillis, Senior Vice President, Devices, acquired 38,078 shares of BioCardia common stock from vested Restricted Stock Units (RSUs) on December 8, 2025, valued at $1.37 per share.
• 15,172 shares were withheld by BioCardia to satisfy income tax, withholding, and remittance obligations related to the RSU vesting.
• Gillis's direct beneficial ownership of common stock following these transactions is 31,874 shares.
• Gillis also acquired 20,000 stock options with an exercise price of $1.37 per share, granted on December 8, 2025, and expiring on December 8, 2035.
• These stock options will vest at a rate of 1/48th of the shares monthly, starting January 8, 2026, subject to continued service.
• Total derivative securities beneficially owned after the transaction is 31,697.

Sentiment

Score: 7

Explanation: The filing reflects standard executive compensation, including RSU vesting and new option grants, which are generally positive for executive retention and alignment with shareholder interests, despite the tax-related share withholding.

Positives

• Senior Vice President Edward M. Gillis received 38,078 shares of common stock from vested RSUs, indicating continued compensation and alignment with shareholder interests.
• Gillis was granted 20,000 new stock options, providing a long-term incentive tied to the company's stock performance and executive retention.

Negatives

• 15,172 shares were withheld by the Issuer to cover income tax obligations related to the RSU vesting, reducing the immediate net share gain for the reporting person.

Future Outlook

The newly granted stock options will vest monthly over 48 months, starting January 8, 2026, contingent upon the reporting person's continued service as a provider.

Industry Context

This is a routine insider transaction related to executive compensation, which is a standard practice across all industries for publicly traded companies. It does not provide specific industry-related insights or trends.

Stakeholder Impact

• Shareholders: The grant of stock options and vesting of RSUs aligns executive incentives with shareholder value creation. The withholding of shares for taxes has a minor dilutive effect on outstanding shares but is a standard practice.
• Employees: Reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• The stock options will continue to vest monthly, with the first vesting on January 8, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation (RSU vesting and option grants) and tax-related share withholding. It does not contain information that would fundamentally alter the investment thesis for BioCardia, Inc. It's a standard disclosure of an insider's equity movements, not indicative of significant operational or strategic changes.

Keywords

BioCardia, BCDA, Form 4, insider transaction, equity compensation, RSU, restricted stock units, stock options, executive compensation, Edward M. Gillis, beneficial ownership